U.S. Markets close in 6 hrs 2 mins
  • S&P 500

    3,443.87
    +8.31 (+0.24%)
     
  • Dow 30

    28,248.89
    +38.07 (+0.13%)
     
  • Nasdaq

    11,521.47
    +36.78 (+0.32%)
     
  • Russell 2000

    1,615.90
    +12.13 (+0.76%)
     
  • Crude Oil

    40.61
    +0.58 (+1.45%)
     
  • Gold

    1,907.30
    -22.20 (-1.15%)
     
  • Silver

    24.89
    -0.36 (-1.41%)
     
  • EUR/USD

    1.1829
    -0.0038 (-0.3194%)
     
  • 10-Yr Bond

    0.8330
    +0.0170 (+2.08%)
     
  • Vix

    28.85
    +0.20 (+0.70%)
     
  • GBP/USD

    1.3106
    -0.0037 (-0.2831%)
     
  • USD/JPY

    104.7100
    +0.1500 (+0.1435%)
     
  • BTC-USD

    12,935.06
    +1,878.05 (+16.99%)
     
  • CMC Crypto 200

    261.06
    +4.96 (+1.94%)
     
  • FTSE 100

    5,774.15
    -2.35 (-0.04%)
     
  • Nikkei 225

    23,474.27
    -92.73 (-0.39%)
     

Company Profile for Axcella Health Inc.

·1 min read

Axcella (Nasdaq: AXLA) is a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators (EMMs) to pioneer a new approach for treating complex diseases and improving health. The company’s product candidates are comprised of EMMs and their derivatives that are engineered in distinct combinations and ratios to simultaneously impact multiple biological pathways. Axcella’s pipeline includes lead therapeutic candidates for non-alcoholic steatohepatitis (NASH) and the reduction in risk of overt hepatic encephalopathy (OHE) recurrence. Additional muscle- and blood-related programs are in earlier-stage development. For more information, please visit www.axcellahealth.com.

Company:

Axcella Health Inc.

Headquarters Address:

840 Memorial Dr., Third Floor

CAMBRIDGE, MA 02139

Main Telephone:

857-320-2200

Website:

www.axcellahealth.com

Ticker:

AXLA(NASDAQ)

Type of Organization:

Public

Industry:

Biotechnology

Key Executives:

CEO: Bill Hinshaw

Investor Relations

Contact:

Jason Fredette

Phone:

7814240946

Email:

jfredette@axcellahealth.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20200924005860/en/